TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The role of innate immune signaling in acute myeloid leukemia (AML) remains unclear.
• Investigating Toll-like receptors (TLRs) in high-risk AML models is crucial for understanding treatment resistance.

Purpose of the Study:

• To elucidate the specific anti-leukemic effects of TLR2 ligands compared to other TLRs in AML.
• To explore the impact of TLR2 signaling on leukemia stem cell (LSC) function and patient survival.

Main Methods:

• Utilized TLR ligands in high-risk AML models.
• Performed single-cell transcriptional profiling to analyze cellular responses.
• Assessed effects on LSC reprogramming, MHC class II expression, and self-renewal.
• Correlated TLR2 and MHCII gene co-expression with AML patient survival data.

Main Results:

• TLR2 ligands demonstrated unique anti-leukemic effects distinct from other TLRs.
• TLR2 signaling induced divergent transcriptional responses in AML cells, affecting proliferation, differentiation, cell death, and immune function.
• TLR2 agonists extended survival in AML-bearing mice by reprogramming LSCs, increasing MHC class II expression, and impairing self-renewal.
• Co-expression of TLR2 and MHCII genes correlated with better overall survival in AML patients.

Conclusions:

• Functional TLR2 signaling antagonizes leukemogenesis in AML.
• TLR2 agonism represents a potential therapeutic strategy for AML treatment.
• Targeting TLR2 offers a promising avenue for improving outcomes in acute myeloid leukemia.